

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



東北虎藥業股份有限公司 NORTHEAST TIGER PHARMACEUTICAL CO., LTD.

(A joint stock limited company incorporated in the People's Republic of China)

(Stock Code: 8197)

PROFIT WARNING

This announcement is made pursuant to Rule 17.10 of the Rules Governing the Listing of Securities on the Growth Enterprise Market ("GEM") of The Stock Exchange of Hong Kong Limited ("GEM Listing Rules") and the Inside Information Provisions (as defined in the GEM Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

On behalf of Board of Directors (the "Board") of Northeast Tiger Pharmaceutical Co., Ltd. (the "Company") and its subsidiary (collectively referred to as "Group"), based on preliminary review of the Group's unaudited consolidated management accounts by the board of directors ("the Directors") of the Company (the "Board"), the Board wishes to inform the shareholders of the Company (the "Shareholders") and potential investors that the Company may record a significant decrease in net profit and will record loss for the year ended 31 December 2014 as compared to that of the corresponding period in 2013, primarily attributable to the following factors:

1. other revenue from Bad debts recovered recorded approximately RMB12,815,000 for the year ended 31 December 2013, and there was no such revenue for the year ended 31 December 2014;
2. general, administrative and other operating expenses increased dramatically due to RMB90,000,000 to be paid by Fu Man Shan Zhen (a subsidiary of the Group) in cash in the coming 18 years recognized as long-term receivable resulting in a fair value loss arising from the settlement arrangement signed on 14 March 2014.

The information contained in this announcement is only based on the preliminary assessment by the management of the Company of the unaudited consolidated management accounts of the Company for the year ended 31 December 2014 and is not based on any figure or information which has been audited or reviewed by the Company's auditors. The Company is in the process of finalising the annual results of the Group for the year ended 31 December 2014. Details of the Group's financial information and performance will be disclosed when the Group's annual results for the year ended 31 December 2014 are announced.

Shareholders and potential investors should exercise caution when dealing in the shares of the Company.

By Order of the Board

Liu Yang
Chairman

Jilin, the PRC
13 February 2015

As at the date of this announcement, the Company's executive directors are Liu Yang, Guo Feng and Qin Haibo and the Company's independent non-executive directors are Lam Kai Yeung, Niu Shu Min and Zhao Zhen Xing.

This announcement will remain on the "Latest Company Announcements" page of the GEM website at <http://www.hkgem.com> for at least 7 days from the day of its posting.